Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects

References

• DiPette DJ, Skeete J, Ridley E, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. J Clin Hypertens. 2019;21(1):4–15. doi:10.1111/jch.13426
   Web of Science ®Google Scholar
• Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens. 1993;6(11 Pt 2):303S–308S. doi:10.1093/ajh/6.11.303s
   PubMed Web of Science ®Google Scholar
• Kim BJ, Cho KI, Kwon HM, et al. Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study. Clin Hypertens. 2022;28(1):7. doi:10.1186/s40885-021-00184-0
   PubMedGoogle Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443–462. doi:10.2165/00003495-200262030-00003
   PubMed Web of Science ®Google Scholar
• Menditto E, Orlando V, De Rosa G, et al. Patient centric pharmaceutical drug product design-the impact on medication adherence. Pharmaceutics. 2020;12(1). doi:10.3390/pharmaceutics12010044
   PubMed Web of Science ®Google Scholar
• Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15(4):291–300. doi:10.1111/dom.12015
   PubMed Web of Science ®Google Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–614. doi:10.1007/s11606-008-0544-x
   PubMed Web of Science ®Google Scholar
• Molina de Salazar DI, Coca A, Alcocer L, Piskorz D. The rationale for using fixed-dose combination therapy in the management of hypertension in Colombia: a narrative review. Am J Cardiovasc Drugs. 2024;24(2):197–209. doi:10.1007/s40256-024-00634-8
   PubMed Web of Science ®Google Scholar
• Essa M, Ross JS, Dhruva SS, Desai NR, Spatz ES, Faridi KF. Utilization of fixed-dose combination treatment for hypertension in medicare and Medicaid from 2016 to 2020. Circ Cardiovasc Qual Outcomes. 2024;e010697. doi:10.1161/CIRCOUTCOMES.123.010697
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mehta PM, Jacobson T, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(4):1199–1209. doi:10.1038/s41591-024-02896-w
   PubMed Web of Science ®Google Scholar
• Manzi G, Recchioni T, Badagliacca R, Papa S, Vizza CD. Fixed-dose combination therapy in pulmonary arterial hypertension: pros & cons. Int J Cardiol. 2024;406:132003. doi:10.1016/j.ijcard.2024.132003
   PubMed Web of Science ®Google Scholar
• Kim H, Choi HY, Kim YH, et al. Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug Des Devel Ther. 2018;12:815–821. doi:10.2147/DDDT.S158408
   PubMed Web of Science ®Google Scholar
• Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Des Devel Ther. 2017;11:3461–3469. doi:10.2147/DDDT.S146863
   PubMed Web of Science ®Google Scholar
• Noh YH, Lim HS, Kim MJ, et al. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Clin Ther. 2012;34(7):1625–1635. doi:10.1016/j.clinthera.2012.05.010
   PubMed Web of Science ®Google Scholar
• Kim CH, Kang SI, Shin D. Pharmacokinetic interaction between telmisartan and rosuvastatin/ezetimibe after multiple oral administration in healthy subjects. Adv Ther. 2021;38(2):1094–1105. doi:10.1007/s12325-020-01592-8
   PubMed Web of Science ®Google Scholar
• Althera Pharms. Rosuzet (rosuvastatin and ezetimibe) [package insert]. US Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213072s000lbl.pdf. Accessed March 23, 2021.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Twynsta (telmisartan/amlodipine) [package insert]. US Food and Drug Administration; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022401s019lbl.pdf. Accessed February 1, 2018.
   Google Scholar
• Son M, Guk J, Kim Y, et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study. Clin Ther. 2016;38(8):1845–1857. doi:10.1016/j.clinthera.2016.06.011
   PubMed Web of Science ®Google Scholar
• Son M, Kim Y, Lee D, et al. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. Clin Ther. 2014;36(8):1147–1158. doi:10.1016/j.clinthera.2014.06.007
   PubMed Web of Science ®Google Scholar
• Hu M, Lee HK, To KK, et al. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Eur J Clin Pharmacol. 2016;72(12):1471–1478. doi:10.1007/s00228-016-2130-1
   PubMed Web of Science ®Google Scholar
• Huh KY, Lee SW, Lee SB, Kim KT, Jang IJ, Lee S. Pharmacokinetic interaction among ezetimibe, rosuvastatin, and telmisartan. Clin Pharmacol Drug Dev. 2021;10(11):1290–1296. doi:10.1002/cpdd.926
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, Pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–494. doi:10.2165/00003088-200544050-00002
   PubMed Web of Science ®Google Scholar
• Hirvensalo P, Tornio A, Launiainen T, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics-a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 2020;108(4):885–895. doi:10.1002/cpt.1928
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129(8):1748–1754. doi:10.1038/sj.bjp.0703235
   PubMed Web of Science ®Google Scholar
• Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol. 2001;41(9):943–949. doi:10.1177/00912700122010915
   PubMed Web of Science ®Google Scholar
• Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2012;30(5):e234–e241. doi:10.1111/j.1755-5922.2011.00290.x
   PubMed Web of Science ®Google Scholar
• Weiss J, Sauer A, Divac N, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010;31(2–3):150–161. doi:10.1002/bdd.699
   PubMed Web of Science ®Google Scholar
• Yang J, Li LJ, Wang K, et al. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacol Sin. 2011;32(1):116–125. doi:10.1038/aps.2010.169
   PubMed Web of Science ®Google Scholar
• Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res. 2009;37(6):1662–1679. doi:10.1177/147323000903700602
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006;26(4):469–478. doi:10.1592/phco.26.4.469
   PubMed Web of Science ®Google Scholar